Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SP-Reference-Cited by-同舟云学术

Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SP

Published:2017-05-04 Issue:3 Volume:91 Page:387-395
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Campos Carlos M.¹^ORCID,Caixeta Adriano¹,Franken Marcelo¹,Bartorelli Antonio L.²,Whitbourn Robert J.³,Wu Chiung-Jen⁴,Li Paul Kao Hsien⁵,Rosli Mohd Ali⁶,Carrie Didier⁷,De Bruyne Bernard⁸,Stone Gregg W.⁹¹⁰,Serruys Patrick W.¹¹,Abizaid Alexandre¹²,

Affiliation:

1. Department of Cardiology, Hospital Israelita Albert Einstein; São Paulo Brazil

2. Centro Cardiologico Monzino, IRCCS; Milan Italy

3. Department of Cardiology, St Vincent's Hospital; Fitzroy Victoria Australia

4. Department of Cardiology, Chang Gung Memorial Hospital; Niao-Sung Hsiang Taiwan

5. Department of Cardiology, National Taiwan University Hospital; Taipei Taiwan

6. Department of Cardiology, Institute Jantung Negara; Kuala Lumpur Malaysia

7. Department of Cardiology, Hôpital de Rangueil CHU; Toulouse France

8. Department of Cardiology, Cardiovascular Center Aalst; Belgium

9. Department of Interventional Cardiology, Columbia University Medical Center; New York

10. Cardiovascular Research Foundation; New York

11. International Centre for Circulatory Health, NHLI, Imperial College London; United Kingdom

12. Department of Interventional Cardiology, Instituto Dante Pazzanese de Cardiologia; São Paulo Brazil

Funder

Abbott Vascular

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Reference35 articles.

1. Assessing bioresorbable coronary devices: Methods and parameters;Garcia-Garcia;JACC. Cardiovasc Imaging,2014

2. Everolimus-eluting bioresorbable stent vs. Durable polymer everolimus-eluting metallic stent in patients with st-segment elevation myocardial infarction: Results of the randomized absorb st-segment elevation myocardial infarction-trofi ii trial;Sabate;Eur Heart J,2016

3. Impact of the everolimus-eluting bioresorbable scaffold in coronary atherosclerosis;Campos;Rev Esp Cardiol,2016

4. Differential impact of five coronary devices on plaque size: Insights from the absorb and spirit trials;Garcia-Garcia;Int J Cardiol,2014

5. 1-year outcomes with the absorb bioresorbable scaffold in patients with coronary artery disease: A patient-level, pooled meta-analysis;Stone;Lancet,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Everolimus-eluting bioresorbable scaffolds and metallic stents in diabetic patients: a patient-level pooled analysis of the prospective ABSORB DM Benelux Study, TWENTE and DUTCH PEERS;Cardiovascular Diabetology;2020-10-02

2. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus;The American Journal of Cardiology;2019-10

3. The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study;Netherlands Heart Journal;2019-06-13